Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma

BMC Cancer

Research Article

Jun-ye Wang¹  Lan-jun Zhang¹  Mu-sheng Zeng²  Man-zhi Li²  Wan-li Liu²  Su Guan²  Li-hua Xu²  Qing-li Kong²  Li-bing Song²  Xian-zhi Guo³  Ge Zhang⁴  Yu-min Chen⁴ 

[1] Department of Experimental Research, Sun Yat-sen University cancer center, Guangzhou, China;Department of Thoracic Surgery, Sun Yat-sen University cancer center, Guangzhou, China;Department of Experimental Research, Sun Yat-sen University cancer center, Guangzhou, China;State Key Laboratory of Oncology in South China, Guangzhou, China;Department of Medical Oncology, The Central Hospital of Xuhui District, Shanghai, China;School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China;

关键词: Esophageal Squamous Cell Carcinoma;    Esophageal Carcinoma;    Esophageal Squamous Cell Carcinoma Patient;    Esophageal Cancer Patient;    Esophageal Squamous Cell Carcinoma Tissue;   

DOI  :  10.1186/1471-2407-10-467

 received in 2009-09-09, accepted in 2010-09-01,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundOverexpression of Bmi-1 has been observed in a variety of cancers, and it has been suggested to be an independent prognostic marker for the patients. The objective of this study was to determine the level of Bmi-1 expression or its autoantibodies in human esophageal squamous cell carcinoma (ESCC) and to correlate it with clinicopathologic data.MethodsWe first examined Bmi-1 expression in ESCC cell lines and tumor samples by RT-PCR and Western blot analysis. We then analyzed Bmi-1 protein expression in 171 clinicopathologically characterized ESCC cases by immunohistochemistry. In addition, we detected its autoantibodies in sera of patients with ESCC by ELISA.ResultsWe found that Bmi-1 expression was higher in the immortalized cells, cancer cell lines and most cancer tissue than in non-tumorous control tissue at both mRNA and protein level. In addition, Bmi-1 expression was observed in 64.3% (110 of 171) archive ESCC specimen by immunohistochemistry analysis, and the location of Bmi-1 in ESCC was in the nuclei instead of cytoplasm of tumor cells. There was a significant difference of Bmi-1 expression in patients categorized according to stage (P = 0.003) and pN classification (P = 0.047). Multivariate analysis suggested that Bmi-1 expression was an independent prognostic marker for ESCC patients. A prognostic significance of Bmi-1 was also found in the subgroup of T3~T4 and N1 tumor classification. Bmi-1 autoantibodies were detected in sera of 39.0% (62 of 159) ESCC patients. The correlations between anti-Bmi-1 antibodies and tumor stage (P = 0.040), or lymph node status (P < 0.001) were significant.ConclusionsOur results suggest that Bmi-1 protein is a valuable marker of ESCC progression. The presence of Bmi-1 autoantibodies in sera from patients with ESCC may have clinical utility in esophageal cancer diagnosis.

【 授权许可】

Unknown   
© Liu et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.